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Abstract
Gap-junction  connexin  (Cx)  channels  are  important  determinants  of  myocardial
conduction  and  synchronization  that  is  crucial  for  heart  function.  Hypertension-
induced structural remodeling is associated with an increased risk of life-threatening
arrhythmias and heart failure in both humans and experimental animals. Recent studies
suggest that abnormal distribution and/or downregulation of Cx43 accompanied with
altered protein kinase C (PKC)ε signaling in spontaneously hypertensive rats were
linked with increased propensity to ventricular fibrillation compared to normotensive
rats. By contrast, the long-term treatment of hypertensive rats with cardioprotective
compounds  such  as  melatonin,  omega-3  fatty  acids,  or  red  palm  oil  resulted  in
protection from lethal arrhythmia. Their antiarrhythmic effect was attributed to the
attenuation of abnormal Cx43 topology and modulation of Cx43 mRNA as well as
protein  expression  and  its  functional  phosphorylated  forms.  The  latter  might  be
attributed  to  upregulation  of  PKCε.  It  appears  that  maladaptive  consequences  of
hypertension resulting in abnormal myocardial distribution of Cx43 and its downre‐
gulation can contribute to arrhythmogenesis and occurrence of malignant arrhyth‐
mias. On the other hand, the attenuation of myocardial Cx43 abnormalities by treatment
with melatonin, omega-3 fatty acids, or red palm oil confers arrhythmia protection in
rodent  model  of  essential  hypertension.  Findings  uncover  novel  mechanisms  of
cardioprotective effects  of  melatonin,  omega-3 fatty acids,  and red palm oil.  Well-
designed  clinical  trials  are  needed  to  explore  antiarrhythmic  potential  of  these
compounds in human essential hypertension.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Different  types  of  epidemiologic  studies,  including  a  growing  number  of  large  cohort
studies and interventional trials in different population groups, have consistently shown
that there is a strong positive association between hypertension and cardiovascular diseases
(CVDs),  and  that  lowering  the  blood  pressure  helps  to  improve  cardiovascular  health.
Hypertension is  the  leading risk  factor  for  the  development  of  CVD, with men exhibit‐
ing  a  higher  arterial  pressure  than  women  during  the  ages  from  20  to  65.  Up  until
menopause, there are significant sex differences in blood pressure, vascular reactivity, and
renal function [1].
Hypertension is a multifactorial process. Environmental factors and the genetic component
as well as epigenetic inheritance contribute significantly to essential hypertension [2] that is
known to be on rise in the human population. Sympathetic nervous system plays a major
role in the maintenance of hypertension and the rostral ventrolateral medulla is the main
source of this sympathetic activation. It is proposed that melatonin-induced epigenetic
modifications in the neurons of area postrema are implicated in this process [3]. Sympathet‐
ic activation in hypertension is accompanied by oxidative stress and inflammation as by-
product [4]. These undesired processes might be ameliorated by interventions with
compounds possessing antioxidant and free radical-scavenging ability, for example, melato‐
nin, statins, adrenergic beta receptor blockers, and omega-3 fatty acids. Patients with
uncontrolled essential hypertension have elevated concentrations of superoxide anion,
hydrogen peroxide, lipid peroxides, endothelin, and transforming growth factor-beta with a
simultaneous decrease in endothelial nitric oxide, superoxide dismutase, vitamin E, and long-
chain polyunsaturated fatty acids (PUFAs) [5–7]. The implication of redox signaling and
lower omega-3 index is suggested in the pathogenesis of essential hypertension in animal
models as well [8, 9]. Omega-3 fatty acids exhibit wide-ranging biological actions [6] that
include the regulation of renal sodium excretion and vasomotor tone, partly by decreasing
the production of vasocostrincting and anti-inflammatory eicosanoids. Omega-3 fatty acids
also activate the parasympathetic nervous system. It is proposed that the availability of
adequate amount of omega-3 fatty acids during the critical periods of growth prevents the
development of hypertension in adulthood [10].
Hypertension is a major risk factor for cardiovascular injury resulting in heart attack, conges‐
tive heart failure, stroke, as well as sudden arrhythmic death [11, 12]. The latter is associated
with myocardial structural remodeling that follows hypertension, such as hypertrophy and
fibrosis. This remodeling is accompanied by changes in expression, distribution, and function
of cell membrane ion channels, intercellular gap-junction connexin-43 (Cx43) channels, Ca2+-
cycling proteins, and extracellular matrix composition [13–16]. Mentioned remodeling
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predisposes to arrhythmogenic mechanisms including early or delayed after-depolarization
and reentry of excitation, facilitating life-threatening ventricular tachycardia (VT) and
ventricular fibrillation (VF).
2. Hypertension-related gap junctions and connexin-43 remodeling
Changes in cardiac workload due to pressure or volume overload induce hypertrophic growth
of individual myocytes. Hypertrophy of cardiomyocytes counteracts the increased wall
tension (Laplace's law), and is therefore often considered as compensated hypertrophy [17].
However, prolonged state of hypertrophy is accompanied by maladaptation that promotes
progression into heart failure (decompensated hypertrophy). Typical ultrastructural altera‐
tions of cardiomyocytes from the left ventricle of old spontaneously hypertensive rats
(frequently used model mimicking essential hypertension in humans) are demonstrated in
Figure 1. Representative electron microscopic images demonstrating cardiomyocytes and intercellular junctions in the
left ventricles of spontaneously hypertensive rat hearts. (A) Conventional ultrastructure showing electron-dense mito‐
chondria (m), adhesive fascia adherens (FA) junctions at the intercalated disk, and peripheral gap junction (arrows) on
the lateral sides of the cardiomyocytes. (B) Development of lateral gap junctions following the formation of adhesive
junctions (AJs) and high amounts of ribosomes (R) and dense mitochondria (m) are seen in young hypertensive rat
heart at compensate stage of hypertrophy. (C) Severely injured cardiomyocytes exhibiting edematous mitochondria,
myocytolysis, pronounced reduction of adhesive fascia adherens (FA) junctions, and loss of gap junctions are sporadi‐
cally seen in the myocardium of old hypertensive rats at early decompensate stage of hypertrophy.
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Figure 1. The cardiac remodeling process is characterized by both structural and electrical
disorders that decrease the electrical stability of the heart [16, 18]. A hallmark of the electrical
changes with regard to impulse conduction is an impairment of electrical coupling due to
abnormal expression of Cx43-constituted gap junctions. Available data suggest that particu‐
larly spatial heterogeneity and severity of Cx43 channels dysfunction throughout myocardium
affects myocardial conduction and electrical properties of the heart. In addition to structural
remodeling, hypertension likewise other systemic or heart disease and proarrhythmogenic
conditions are linked with oxidative stress and/or inflammation [4, 7, 9]. This pathology
contributes to the impairment of intercellular junctions and communication due to the
acceleration of Cx43 degradation and/or dysfunction as well as other Cx43-interacting proteins
[19]. Cascade events induced by hypertension resulting in an increased risk for malignant
arrhythmias are demonstrated in Figure 2.
Figure 2. Scheme showing possible myocardial alterations of cardiomyocytes as well as Cx43 expression and distribu‐
tion that might increase a risk for SCD in spontaneously hypertensive rats and also most likely in patients suffering
from essential hypertension.
Several studies have described changes in the number, size, and distribution of myocardial
gap junctions during hypertrophic heart disease. In general, Cx43 expression appears to be
unaltered or upregulated during the initial and compensatory phase of hypertrophy but they
are always redistributed along the cardiomyocyte surface (Figures 3 and 4). Cx43 expression
and the number of intercalated disk-related gap junctions are reduced when the hypertrophy
becomes maladaptive, accompanied by severe cardiomyocyte injury (Figures 3 and 4) and
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interstitial fibrosis resulting in progression to heart failure [16]. Kostin et al. [15] reported that
in the left ventricles of pressure-overloaded human hearts with aortic stenosis, Cx43 expression
was increased in the compensated hypertrophic stage, but was decreased and heterogeneously
distributed throughout the ventricles in the period of decompensated hypertensive heart. The
decreased expression of Cx43 at the protein level is accompanied by a reduction of Cx43
mRNA, suggesting that the downregulation of Cx43 in hypertrophic heart disease is regulated
at the transcriptional level. Downregulation and/or heterogeneous redistribution of Cx43
channels is often associated with abnormal conduction that facilitates arrhythmias (Figure 2),
although there seems to be a large reserve before reduced intercellular coupling becomes
arrhythmogenic [18]. Interestingly, hypertrophic cardiomyopathy, the most common genetic
disease of the myocardium, is also characterized by cardiomyocyte hypertrophy, myofibrillar
disarray, fibrosis, and miss-localization of Cx43 linked with changes in myocardial conduction
and prolonged QRS interval [20]. Consequently, there is a high risk of sudden arrhythmic
death, especially in young adults (including competitive athletes).
Figure 3. Representative electron microscopic images demonstrating altered topology of myocardial gap junctions in
hypertensive rat hearts. (A) Lateraly situated gap junctions in the vicinity of adhesive junctions are seen in young rats
frequently at compensated stage of hypertrophy. (B) Internalization of intercalated disk-related gap junctions (arrows)
is often seen in old rats at decompensated stage of hypertrophy. Abbreviations: s – sarcolemma, D – desmosome, FA –
fascia adherens junction, m – mitochondria, bar 1 μm.
In the context of myocardial remodeling and Cx43 alterations, it is important to note that
microRNA-1 has an essential regulatory impact in cardiogenesis, cardiac hypertrophy, and
cardiac electrophysiology. The latter is due to its ability to modulate the expression levels of
molecular targets that modulate the electrical properties of cardiac cells. These targets are
GJA1-encoding Cx43 and KCNJ2-encoding potassium channel protein that determine myo‐
cardial conduction velocity and repolarization [21]. Downregulation of microRNA-1 at the
early stage of cardiac hypertrophy was associated with an increased Cx43 protein levels and
enhanced Cx43 phosphorylation. The latter correlated with the displacement of Cx43 from the
gap junctions that facilitated ventricular tachyarrhythmias [22]. In turn, it is most likely that
decompensated hypertrophic stage accompanied by a decrease of Cx43 gene transcripts and
protein levels might result from upregulation of microRNA-1. This view is supported by
findings that inflammation (known to be implicated in the pathogenesis of hypertension)
represses Cx43 expression via upregulation of microRNA-1 and potentiates arrhythmogenesis
by targeting GJA1 [23, 24].
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Taken together, it can be hypothesized that the prevention or attenuation of maladaptive
myocardial Cx43 remodeling and dysfunction induced by hypertension could decrease a risk
of arrhythmic death and heart failure [18, 25].
Figure 4. Representative images of myocardial Cx43-immunofluorescence in the left ventricles of young (WKY) and
old (LEW) normotensive rats as well as young (ySHR) and old (oSHR) spontaneously hypertensive rat hearts. Note:
conventional topology of Cx43-positive gap junctions at the intercalated disks (thin arrows) and enhanced expression
of Cx43 on lateral surfaces (short arrows) of the cardiomyocytes in young rats at compensate stage of hypertrophy and
pronounced mislocalization of Cx43 due to fibrosis in old rats at decompensate stage of hypertrophy. ESC, extracellu‐
lar space. Magnification, objective ×40.
3. The role of myocardial Cx43 in protecting from malignant arrhythmias
Therapy to prevent death due to arrhythmias involves invasive procedures, that is, implant‐
able cardioverter defibrillator to protect from sudden cardiac death when VF occurs, catheter
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ablation of arrhythmogenic loci, and resynchronization devices for supporting myocardial
synchronization and thereby reducing arrhythmia risk. Blockade of ion current by antiar‐
rhythmic drugs is often ineffective and may even cause proarrhythmia that can increase
mortality. As a result, the effort to develop new antiarrhythmic drugs directed at specific ion
channels has decreased dramatically. However, mentioned invasive treatment did not prevent
the occurrence and/or recurrence of life-threatening arrhythmias. Moreover, these interven‐
tions decrease the quality of life and can also be accompanied by various complications.
Therefore, novel approach fighting arrhythmia-related sudden cardiac death and stroke is
warranted. Considering the crucial role of intercellular coupling and communication to ensure
synchronized myocardial contraction, it seems relevant to suggest the implication of these
factors in the prevention of arrhythmias.
The novel approach is based on a prevention or attenuation of the development of arrhyth‐
mogenic substrates in relation to Cx43 channel function to reduce a risk of arrhythmia
occurrence [25, 26]. Taking into consideration, events involved in the development of malig‐
nant arrhythmias include oxidative/nitrosative stress, myocardial hypertrophy and/or fibrosis,
Cx43 remodeling, and conduction disturbances; the action of antiarrhythmic compounds is
expected to include one or more steps in cascade of events [25]. Consistent with it, the
“upstream” drug therapy is of great interest aiming to prevent or eliminate arrhythmogenic
substrates and triggers. Lipid-lowering drugs, statins, and some antihypertensive drugs are
known to exhibit antiarrhythmic effects likely due to the attenuation of myocardial remodeling
(hypertrophy, fibrosis) that affects intercellular coupling mediated by Cx43 channels. In
addition, these pharmacological compounds exert antioxidant and anti-inflammatory efficacy.
All these actions seem to preserve the adequate myocardial Cx43 levels and topology. Direct
and/or indirect salutary modulation of Cx43 channel function may confer protection from
malignant arrhythmias. Despite the increasing number of experimental studies supporting
this idea, there are still many questions to be answered by further research. The topic is
challenging to address in experimental as well as in clinical settings or when considering the
development of new antiarrhythmic drugs. This article focuses on the benefit of non-pharma‐
cological compounds in spontaneously hypertensive rats, a rodent model mimicking human
essential hypertension. It demonstrates novel pleiotropic effects of melatonin and new
mechanisms of omega-3 fatty acids and antioxidant-rich red palm oil (RPO) actions that are
associated with the modulation of myocardial Cx43.
3.1. Antihypertensive and antiarrhytmic effects of melatonin
Melatonin can reduce blood pressure through the (1) direct effect on hypothalamus, (2) by its
antioxidant properties that lower blood pressure, and (3) by decreasing the amount of
catecholamines [27]. Hypotensive effect of melatonin could also be mediated by its direct effect
on blood vessels or by decreasing serotonin production that is crucial in the inhibition of
sympathetic and stimulation of parasympathetic system [28]. Melatonin could affect changes
in blood pressure also through its specific melatonin receptors localized in the peripheral
vessels or in parts of central nervous system that directly participate in the control of blood
pressure [29].
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It appears that melatonin in addition to its circadian rhythm regulation exerts a hypotensive
effect, and it can modulate cellular redox state and improve the function of the cardiovascular
system in pathological conditions. Elderly population has reduced circulating melatonin levels
[30, 31]. Decrease of melatonin was also registered in patients suffering from primary hyper‐
tension compared with normotensive individuals [32]. Increased melatonin concentration in
elderly patients suffering from hypertension may thus be of crucial therapeutic importance.
Patients suffering from coronary heart disease, the most typical complication of chronic
hypertension, exhibited over fivefold lower level of serum melatonin at night compared with
the control group [33]. Likewise, patients demonstrating a “non-dipping profile” of nocturnal
arterial pressure exhibited decreased nocturnal melatonin secretion compared with the
patients showing a “dipping profile” [34, 35]. The study of Kedziora-Kornatowska et al. [36]
confirms the benefit of melatonin supplementation on parameters of oxidative stress in elderly
patients suffering from primary hypertension and suggests that melatonin supplementation
can be considered as a supporting therapy in the treatment of hypertension. In “non-dippers,”
a significant hypotensive effect was observed [37]. Melatonin is effective in lowering blood
pressure in essential hypertensive patients [38] and in patients with nocturnal hypertension
[39]. Antihypertensive effect of exogenous melatonin is reported in numerous experimental
studies [29, 39–43].
In addition to antihypertensive effects of melatonin, in vitro and in vivo experimental studies
demonstrate its acute antiarrhythmic effects [44–46]. Melatonin appears to be effective even in
physiological concentrations. On the other hand, arrhythmias score was significantly higher
after coronary artery ligation in pinealectomized rats compared with controls [47, 48]. In almost
all of the above mentioned studies, melatonin-induced cardioprotection and antiarrhythmic
effects are attributed to its free radical-scavenging potential [44, 49, 50]. Of note, melatonin has
several features that are of clinical interest. It has low toxicity, crosses all types of biological
barriers (i.e., blood-/brain barrier and placenta), and it can easily enter into all cell compart‐
ments including mitochondrias, producers of free radicals [50].
3.2. Antihypertensive and antiarrhythmic effects of omega-3 PUFA
Numerous studies report salutary effects of omega-3 PUFA, that is, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) on CVD risk factors [51]. These effects include (1)
lowering of serum triglycerides via reduction in hepatic triglycerides production, (2) lowering
blood pressure via improved endothelial cell function, (3) decreasing platelet aggregation via
reduction in prothrombotic prostanoids, (4) decreasing inflammation via reduction in four-
series leukotriene production, and (5) protection from arrhythmia via modulation of electro‐
physiological properties of cardiac myocytes. Beneficial effects of omega-3 PUFA on CVD risk
factors in children including regulation of blood pressure, during childhood, and adolescence
are recently reviewed [52]. Systematic meta-analysis suggests that high doses of omega-3
PUFA (~3 g/day) produce a small but significant decrease in systolic blood pressure in older
and hypertensive subjects [53].
Observational and interventional studies indicate that dietary omega-3 PUFA may be effective
in preventing cardiac arrhythmias and sudden cardiac death. The strongest evidence suggest‐
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ing an antiarrhythmic effect of omega-3 PUFA, resulting in significant reduction of sudden
cardiac death, provides large GISSI-Prevenzione trial [54]. Antiarrhythmic actions observed
in both clinical and experimental conditions are mostly associated with myocardial infarction
or post-infarction-related malignant arrhythmias. Some studies, in particular clinical trials, do
not clearly demonstrate the antiarrhythmic effects of omega-3 PUFA [55–57]. To explain the
discrepancy of the results, it is suggested that the effectiveness of omega-3 PUFA treatment
might depend on the mechanism of cardiac arrhythmia, dose, and the route of omega-3 PUFA
administration [58]. Moreover, the efficacy of omega-3 PUFA supplementation in clinical trials
should be adjusted to initial basal levels of omega-3 PUFA as well as medical treatment
regimen of patients. Multiple mechanisms of cardioprotective and antiarrhythmic effects of
omega-3 PUFA are suggested, including ion channel function modulation and prevention of
pressure overload-related cardiac remodeling [59].
3.3. Cardioprotective and antiarrhythmic effects of red palm oil
The link between dietary fats and cardiovascular diseases has initiated a growing interest in
a dietary red palm oil research. RPO is obtained from the orange-red mesocarp of the fruit of
a tropical plant known as oil palm (Elaeis guineensis) [60]. Besides unsaturated and saturated
fatty acids, it contains high concentration of antioxidants such as vitamin A (carotenes), pro-
vitamin E—namely tocotrienols, tocopherols, coenzyme Q10, and lycopene [61–63]. In spite of
its high level of saturated fatty acid content, RPO intake does not promote vascular disease.
On the contrary, the benefits of RPO on health include reduction in the risk of arterial throm‐
bosis and/or atherosclerosis, platelet aggregation, reduction in blood pressure [61], inhibition
of endogenous cholesterol biosynthesis, and a reduction in oxidative stress [62]. Oxidative
stress and the severity or progression of disease have stimulated further interest in the potential
role of RPO (a cocktail of natural antioxidants) to improve redox status. Experimental studies
suggest that the cardioprotective effects of RPO may not only be due to the high antioxidant
content but could also be mediated by the ability of RPO to modulate signaling events during
ischemia and reperfusion [63, 64]. The cardioprotective effects of the tocotrienol-rich fraction
have been attributed to the effect of tocotrienol to modulate the Akt signaling, thus generating
a survival signal during reperfusion [62]. Beneficial effects of RPO are partially mediated via
the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) signaling pathway [64].
These findings strongly suggest that PI3K-Akt pathway may play an important role in the
RPO-induced cardioprotection. However, this evidence is circumstantial since PI3K has
several downstream targets other than Akt. Specific inhibition of Akt will allow to elucidate
the importance of Akt on post-ischemic functional recovery in RPO-supplemented animals.
RPO supplementation is associated with an increased dual phosphorylation of Akt on Ser473
and Thr308 residues indicating that the optimal activation of Akt requires phosphorylation on
both Ser473 and Thr308 residues [65, 66]. Recent experimental studies demonstrate that RPO
supplementation offers protection against ischemia/reperfusion injury by improved cardiac
output recovery. Evidence strongly suggests that mitogen-activated protein kinases (MAPKs),
NO-cGMP, and pro-survival PI3K-Akt signaling pathway may be involved in [63, 64, 66–68].
Further studies are needed to explore novel cellular and molecular mechanisms that might be
involved in RPO-related cardioprotection. Data about antiarrhythmic potential of RPO are
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rare. According to the recent study [8], increased susceptibility of hyperthyroid rats to
malignant arrhythmias is partially ameliorated by supplementation with red palm oil and
related mainly to the upregulation of Cx43 and protein kinase C (PKC)ε.
4. Modulation of myocardial Cx43 expression by melatonin
In addition to antiarrhythmic effects of acute administration of melatonin in the setting of
ischemia/reperfusion, its antiarrhythmic efficacy has been recently demonstrated in sponta‐
neously hypertensive rats after long-term administration [43]. Several studies showed that
compared to normotensive rats, spontaneously hypertensive rats are much prone to develop
VF [25]. Consistent with it, the threshold to electrically inducible VF is significantly lower in
hypertensive versus normotensive rats but it is increased in response to melatonin treatment.
This antiarrhythmic effect of melatonin is associated with the enhancement of myocardial Cx43
gene expression (Figure 5A) as well as the total levels of Cx43 protein and its functional
phosphorylated forms in hypertensive and to lesser extent in normotensive Wistar rat hearts
(Figure 6, left panel). Increase of Cx43 phosphorylation could be in part attributed to the
increase of PKCε isoform resulting from melatonin treatment. Moreover, Cx43 immunofluor‐
escence labeling and quantitative image analysis reveal an attenuation of abnormal Cx43
distribution and enhanced myocardial Cx43-positive signal in hypertensive rats treated with
melatonin. These findings strongly indicate that melatonin may modulate Cx43 expression
and distribution in the remodeled heart of hypertensive rats.
Figure 5. Cx43 mRNA expression normalized to actin in the left ventricles of young (A) and old (B) untreated and
omega-3-treated young SHR and normotensive rat hearts. WKYc, untreated WKY rats; WKYo3, WKY rats treated with
omega-3; LEWc, untreated Lewis rats; LEWo3, Lewis rats treated with omega-3; SHRc, untreated SHR; SHRo3, SHR
treated with omega-3 PUFA.Results are mean ± SD of eight hearts,significant difference (P <0.05) * from WKYc (WISc,
LEWc resp.),and # from SHRc.* Modified with permission from [82]; [43]; [78].
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Figure 6. Representative immunoblot (A) showing two phosphorylated and one non-phosphorylated form of Cx43 and
densitometric quantification of total Cx43 expression (B) and its functional phosphorylated forms (C) normalized to
GAPDH in the left ventricles of untreated and melatonin-treated (left panel), and red palm oil-treated (right panel) hy‐
pertensive (SHR) and normotensive (WIS or WKY) rat hearts. Significant difference (P <0.05) * from WKYc (WISc
resp.), and # from SHRc. *Modified with permission from [82]; [43].
However, molecular mechanisms of melatonin effects on myocardial Cx43 are not elucidated
yet. It has been reported that melatonin upregulates Cx43 (mRNA and protein) and enhances
cell-to-cell coupling in human myometrial smooth muscle cells via MT2 receptor and protein
kinase C-dependent manner [69]. It is proposed that melatonin activates phospholipase C
followed by the generation of inositol triphosphate and diacylglycerol. The latter activates
PKC, which can affect transcription factors c-fos and c-jun that are important in the regulation
of Cx43 expression in myometrial cells [70]. Further studies are needed to explore whether this
pathway might be involved in the upregulation of Cx43 in heart muscle as well. The cardio‐
protective and antiarrhythmic effects of acute melatonin treatment in condition of Ischemia/
reperfusion were attributed mainly to its antioxidant and free radical-scavenging activity. It
is most likely that these cardioprotective actions of melatonin are involved in the condition of
oxidative stress induced by hypertension. Consequently, it might result in the preservation of
myocardial Cx43 proteins and protection from its downregulation. Melatonin may be classi‐
fied as a naturally occurring, mitochondrial-targeted antioxidant [71]. This fact is important
when considering the most recent studies [26, 72] showing that arrhythmias could be pre‐
vented by mitochondria-targeted antioxidants rather than by general antioxidants. It also
seems possible that melatonin could protect myocardial Cx43 via inhibiting the activity of
cyclooxygenase 2 and inducible NO synthase caused by chronic inflammation [73]. Hypo‐
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thetical mechanisms of the modulation of cardiac Cx43 channels and protection from malig‐
nant arrhythmias by melatonin are depicted on Figure 7.
Figure 7. Proposed mechanisms of melatonin action on myocardial Cx43 expression and distribution in spontaneusly
hypertensive rat heart. Circulating melatonin via its receptors, MT1 and MT2, activates phospholipase C (PLC) fol‐
lowed by the production of diacylglycerol (DAG), which activates protein kinase C (PKC). PKCε by phosphorylation
of Cx43 can modulate the channel's function as well as its myocardial distribution and subsequently gap-junctional
intercellular communication (GJIC). Activation of PKCα also affects transcription factors c-FOS and cJUN, which bind
to conserved activator protein-1 in the promoter region of Cx43 and hence can increase Cx43 expression. In addition,
melatonin exhibits receptor-independent actions due to its ability to scavenge free radicals. Free radicals enhance the
degradation of Cx43 and melatonin can attenuate this process and preserve myocardial Cx43 levels. Altogether, the
protection of functional Cx43 by melatonin can affect GJIC and improve electrical stability resulting in the decrease of
inducible VF.
5. Modulation of myocardial Cx43 expression by omega-3 PUFA
A direct renin inhibitor, aliskiren, and dietary omega-3 PUFA attenuate electrical remodeling
in renin-angiotensin transgenic rats (another model mimicking human hypertension) most
likely due to the restoration of normal topology of Cx43 [74]. Both treatments also reduce the
QRS and QT interval suggesting an improvement in conduction that could be attributed to
reduced fibrosis and the elimination of lateral distribution of Cx43. Consequently, it results in
the decline of tachyarrhythmia induction. In addition, aliskiren and omega-3 PUFA prevent
hypertension-related inflammation that is generally known to downregulate Cx43 [75].
Antiarrhythmic effects of both omega-3 PUFA and atorvastatin (a hypolipidemic drug with
anti-inflammatory and antioxidant properties) are demonstrated in hereditary hypertrigly‐
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ceridemic rats with elevated blood pressure [76]. The decrease of VF inducibility is associated
with the suppression of hyper-phosphorylation of Cx43 and the restoration of its normal
myocardial topology. Electron microscopy examination reveals that both omega-3 PUFA and
atorvastatin improve the structural integrity of mitochondria, plasma membrane, and
intercellular junctions when compared to untreated diseased rats. This membrane protective
effect may be partially explained by changes in membrane composition [77], that is, increased
incorporation of omega-3 PUFA and decreased cholesterol levels due to treatments. It would
be interesting to know whether atorvastatin affects properties of ion and Cx43 channels as well
as well as myocardial conduction, (likewise omega-3 PUFA), to understand better its antiar‐
rhythmic effect in relation to myocardial Cx43 alterations.
Figure 8. Representative immunoblot (A) showing three forms of Cx43 and densitometric quantification of total Cx43
expression (B) and its functional phosphorylated forms (C), normalized to GAPDH in the left ventricles of untreated
and omega-3-treated young SHR and WKY rat hearts (left panel) as well as in the left ventricles of untreated and ome‐
ga-3-treated old SHR and Lewis rat hearts (right panel). Results are mean ± SD of eight hearts, Significant difference (P
<0.05) * from LEWc, and # from SHRc. *Modified with permission from [78].
Protection from VF due to intake of omega-3 PUFA (i.e., DHA and EPA) and the implication
of myocardial Cx43 are demonstrated in another study [78] using young (compensated stage
of hypertrophy) and old spontaneously hypertensive rats (early decompensated stage of
hypertrophy). Findings show that omega-3 PUFA intake normalizes myocardial Cx43 mRNA
levels in old rats (Figure 5C, D) and Cx43 protein expression as well as its functional phos‐
phorylated status in both young and old hypertensive animals (Figure 8). Enhanced Cx43
phosphorylation might be in part attributed to PKCε that is upregulated by omega-3 PUFA.
The treatment significantly eliminates abnormal Cx43 distribution (Figure 9), diminishes the
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internalization of gap junctions, and improves ultrastructure (integrity) of the mitochondria
in cardiomyocytes of hypertensive rats. These findings clearly indicate that the modulation of
Cx43 channel function and myocardial cell-to-cell coupling by omega-3 PUFA might be
possible.
Figure 9. Representative images of myocardial Cx43-immunofluorescence in the left ventricles of untreated young
(ySHR) and old (oSHR) and omega-3 fatty acid-treated young (ySHRo3) and old (oSHRo3) spontaneously hyperten‐
sive rat hearts. Note: prevalent normal Cx43 distribution at the intercalated disks (thin arrows) and apparent attenua‐
tion of disordered Cx43 distribution (short arrows) as well as reduced fibrosis due to supplementation with omega-3
fatty acids. ESC, extracellular space. Magnification, objective ×40.
Nevertheless, the question arises as to how omega-3 affects myocardial Cx43 expression and
its phosphorylation. It is known that omega-3 PUFA are ligands for the nuclear transcription
factor, peroxisome proliferator-activated receptor (PPAR). It is also known that omega-3 PUFA
might regulate numerous gene expressions and consequently intracellular pathways involved
in protein expression and phosphorylation [79, 80]. The discovery of omega-3 PUFA signaling
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pathways linked with Cx43 modulation may reveal new candidates for antiarrhythmic drug
development. Antiarrhythmic properties of omega-3 PUFA may also include the modulation
of membrane ion current densities and intracellular Ca2+ handling [81]. Available data suggest
that possible mechanisms of omega-3 PUFA (shown in Figure 10) could prevent downregu‐
lation and mislocalization of cardiac Cx43. Consequently, it could lead to suppression in the
incidence of life-threatening arrhythmias.
Figure 10. Diagram for the proposed mechanisms of omega-3 PUFA that could prevent downregulation and mislocali‐
zation of cardiac Cx43. Consequently, it could lead to a reduction in the incidence of life-threatening arrhythmias.
6. Modulation of myocardial Cx43 by red palm oil
It has been, for the first time, demonstrated that there is upregulation of myocardial Cx43 and
suppression of PKCε activation in response to RPO supplementation of male, adult sponta‐
neously hypertensive rats [82]. In this study, Cx43-mRNA (Figure 5D), total Cx43 proteins,
and its phosphorylated forms are increased. Moreover, disordered localization of Cx43 is
attenuated in the left ventricle of RPO-fed hypertensive rats compared with untreated rats.
These alterations are associated with the suppression of early post-ischemic-reperfusion-
related VT and electrically inducible VF. Moreover, it is linked with the improvement of
functional recovery of the heart during post-ischemic reperfusion. However, the treatment
dose of RPO (200 mg/day for 5 weeks) causes downregulation of myocardial Cx43 in normo‐
tensive age-matched rats. It results in poor arrhythmia protection, suggesting overdosing of
Myocardial Connexin-43 is Implicated in the Prevention of Malignant Arrhythmia in Rats Suffering from Essential
Hypertension
http://dx.doi.org/10.5772/63456
199
RPO in healthy rats. Findings indicate that hypertensive rats benefit from RPO intake,
particularly because of its apparent antiarrhythmic effects. This protection can be, in part,
attributed to the upregulation of myocardial Cx43 but not with PKCε activation. In addition,
RPO supplementation reduced blood pressure in hypertensive rats and blood glucose in both
hypertensive and normotensive rats. Taken together, the results indicate that hypertensive rats
benefit from RPO supplementation, particularly due to its apparent antiarrhythmic and post-
ischemic-reperfusion-related cardioprotective effects that can be, in part, explained by the
upregulation of myocardial Cx43. This view is supported by findings that the downregulation
of Cx43 in response to RPO intake of healthy normotensive rats is associated with poor
antiarrhythmic effect.
7. Conclusions and perspectives
Data included in this comprehensive article suggest that the attenuation of hypertension-
induced abnormal and/or restoration of normal myocardial expression and distribution of
Cx43 as well as enhancement of its functional phosphorylated forms along with positive
modulation of PKC signaling by melatonin, omega-3 fatty acids, and red palm oil may be
crucial in their antiarrhythmic mechanisms. Despite “optimal” therapy of patients suffering
from hypertension, there is still urgent need for preventing severe rhythm disorders. In view
of the many missed potential targets for preventing adverse myocardial remodeling, it appears
that the beneficial modulation of Cx43 by melatonin, omega-3 fatty acids, and red palm oil
might be a useful approach in current therapy. Our findings support the prophylactic use of
these non-pharmacological compounds to minimize cardiovascular risk and sudden arrhyth‐
mic death. A novel approach is needed since despite a plethora of available treatment options,
a substantial portion of the hypertensive population has uncontrolled blood pressure. Further
studies should elucidate more in detail mechanisms of myocardial Cx43 modulation in the
context of electrical properties of the heart in response to treatment of hypertension
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